Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02487979 · ClinicalTrials.gov registry record · Phase 2
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02487979: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02487979 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02487979, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase II trial studies how well glembatumumab vedotin works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as glembatumumab vedotin, may find tumor cells and help kill them.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Glembatumumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02487979
The ClinicalTrials.gov registry entry for NCT02487979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02487979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02487979 about?
NCT02487979 is a clinical study titled "Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma". This phase II trial studies how well glembatumumab vedotin works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as glembatumumab vedotin, may find tumor cells and help kill them.
What is the current status of trial NCT02487979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-02-16. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02487979?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Glembatumumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02487979?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.